Meropenem Steriscience (Meropenem)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, weakening the wall and causing osmotic rupture, which leads to bacterial cell death. Its structure confers stability against many β‑lactamases, giving it activity against a wide range of resistant pathogens.

The specific dose and infusion rate of Meropenem Steriscience are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function and local antimicrobial guidelines. Healthcare professionals should follow institutional protocols and adjust dosing as needed for individual patient factors.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus. Women who are breastfeeding should consult their healthcare provider, as the drug may be excreted in breast milk and could affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Meropenem and imipenem share a similar spectrum against many Gram‑negative and Gram‑positive bacteria, but meropenem is generally better tolerated, with a lower risk of seizures and less need for co‑administration of a renal protective agent (cilastatin). Both require dose adjustment in renal impairment, and selection often depends on local resistance patterns and patient-specific factors.

Meropenem Steriscience should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product labeling, typically within 24 hours if kept at controlled room temperature, to maintain potency.

Meropenem Steriscience is administered intravenously, usually as a short infusion over 15‑30 minutes. The infusion rate and duration are determined by the prescriber based on the clinical scenario and patient tolerance. Intravenous administration ensures rapid systemic exposure, which is essential for treating serious infections.

The most serious adverse events include seizures, particularly in patients with renal dysfunction or pre‑existing CNS disorders, and severe hypersensitivity reactions such as anaphylaxis. Additionally, Clostridioides difficile‑associated colitis can develop, requiring prompt recognition and management.

Meropenem Steriscience is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment (unless dose‑adjusted), and those receiving valproic acid, as drug interactions may reduce seizure control.